Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT06281054
  4. Details
NCT06281054 Clinical Trial

Acute Myocardial Infarction in Cancer Patients

Cancer Clinical Trial

Official title:
Risk and Clinical Outcomes of Acute Myocardial Infarction in Patients With Cancer: A Nationwide Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06281054
Other study ID # SMC2023-12-027
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2002
Est. completion date December 31, 2024

Study information
Verified date February 2024
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.

Description:

This study will be conducted using Korean National Health Insurance Service database. Patients who were diagnosed with cancer from 2002 to 2021 will be included in the study. Using the selected patients, current study will analyze the incidence and prognosis of acute myocardial infarction in cancer patients and the prognosis according to the treatment method for acute myocardial infarction will be compared. Primary outcome will be all-cause death. Secondary outcomes will be myocardial infarction, revascularization, hospitalization for heart failure, stroke, and clinically relevant bleeding.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 4500000
Est. completion date December 31, 2024
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients diagnosed with cancer between 2002 and 2021 - Patients who were diagnosed with acute myocardial infarction after cancer diagnosis Exclusion Criteria: - Patients who died during period of cancer diagnosis

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Revascularization
Performing PCI or CABG

Locations
Country Name City State
Korea, Republic of Chonnam National University Hospital, Chonnam National University Medical School Gwangju

Sponsors (2)
Lead Sponsor Collaborator
Samsung Medical Center Chonnam National University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary All-cause death All-cause death which was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea 2-years after diagnosis of acute myocardial infarction
Secondary Myocardial infarction Myocardial infarction is defined as presence of the diagnostic codes (ICD-10 I21, I22) in the primary position during hospitalization 2-years after diagnosis of acute myocardial infarction
Secondary Revascularization Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) 2-years after diagnosis of acute myocardial infarction
Secondary Hospitalization for heart failure Heart failure events requiring hospitalization defined as presence of the diagnostic codes (I110, I130, I132, I255, I420, I425-I429, I43, I50, I971) in the primary position during hospitalization 2-years after diagnosis of acute myocardial infarction
Secondary Stroke Stroke is defined as ischemic stroke (ICD-10 I63, I64) or intracranial hemorrhage (ICD-10 I60-62), combined with the codes of diagnostic brain imaging. 2-years after diagnosis of acute myocardial infarction
Secondary Clinically relevant bleeding Bleeding requiring hospitalization or transfusion 2-years after diagnosis of acute myocardial infarction
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients